Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China
Retrieved on:
Thursday, January 20, 2022
Pharmaceutical, Optical, Medical Supplies, General Health, Health, Medical Devices, Dental, Other Health, Forward-looking statement, Eye, Private Securities Litigation Reform Act, Pharmacy, RX, COVID-19, Hypochlorous acid, COO, Safety, CEO, Medication, U.S. Securities and Exchange Commission, Nasdaq, Bacteria, View, Pain, Skin, Marketing, Infection, Dentistry, Dental care, Scar, Itch, Patent, Cell, Economic development, Hospital, Security (finance), Partnership, Pharmaceutical industry, Salus Medical, Anlicare International, Sonoma Pharmaceuticals, Inc., SALUS MEDICAL, ANLICARE INTERNATIONAL, SONOMA PHARMACEUTICALS, INC.
Sonoma entered into a non-exclusive agreement with Salus Medical to distribute Endocyn root canal irrigant through their existing dental channels.
Key Points:
- Sonoma entered into a non-exclusive agreement with Salus Medical to distribute Endocyn root canal irrigant through their existing dental channels.
- Additionally, on January 18, 2022, Sonoma and Anlicare agreed to cooperate to complete the regulatory work necessary to obtain licenses in China to distribute Sonomas Microcyn technology-based dental and oral products.
- Anlicare will bear the regulatory costs and in return, Sonoma agreed to grant Anlicare exclusive rights for selling and distributing oral and dental care products in China.
- Sonoma Pharmaceuticals, Microcyn, Endocyn and Regenacyn are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.